¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Hypertension secondary to endocrine disorders"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
¿µ¹® endocrine gland ÇÑ±Û ³»ºÐºñ»ù
¼³¸í   
  ½ÅüÀÇ ³»ºÎ·Î ºÐºñ°¡ µÇ¾î¼­ ´Ù¸¥ ¼¼Æ÷ÀÇ ±â´ÉÀ̳ª È°¼ºÀÇ º¯È­¸¦ ÀÏÀ¸Å°´Â ¹°ÁúÀΠȣ¸£¸óÀ» ºÐºñÇϴ °÷À» À̸£´Â ¸»ÀÌ´Ù. ´ëÇ¥ÀûÀΠ³»ºÐºñ»ùÀº °©»ó»ù, ºÎ°©»ó»ù, ºÎ½Å, ÀÌÀÚ, ³úÇϼöü, ³­¼Ò, °íȯ, ¼Ö¹æ¿ï»ù, °¡½¿»ù µîÀÌ´Ù.
  
  ¸¶Áö¸·¿¡ ³ª¿À´Â 2°³ÀÇ ±â°üÀº ³»ºÐºñ ±â´ÉÀ» Çϴ °ÍÀ¸·Î »ý°¢ÀÌ µÇÁö¸¸ È®½ÇÈ÷ ±×°ÍÀÌ ¹«½¼ ±â´ÉÀ» Çϴ Áö¿¡ ´ëÇØ¼± ¾ÆÁ÷±îÁö Á¤È®ÇϰԠ¹àÇôÁöÁö ¾Ê°í ÀÖ´Ù.
  
  ³»ºÐºñ»ù
¿µ¹® secondary infection ÇÑ±Û ÀÌÂ÷°¨¿°
¼³¸í   
  ¾î¶² º´¿øÃ¼ÀÇ °¨¿°¿¡ ÀÇÇÏ¿© º»ÀÎÀÇ ÀúÇ×·ÂÀÌ ¾àÇØÁ³À» ¶§ ¸öÀÇ ´Ù¸¥ ºÎÀ§·Î ÀüÀÌÇÏ¿© ´Ù½Ã °¨¿°À» ÀÏÀ¸Å°´Â °Í. º´¿øÃ¼°¡ ÀÎü¿¡ Ä§ÀÔÇÏ¿© Æ¯Á¤ÇÑ ±â°üÀ̳ª Á¶Á÷¿¡¼­ º´¿øÃ¼°¡ Áõ½ÄÇϰí, ±×°÷¿¡ Æ¯À¯ÀÇ º´Å͸¦ ÀÏÀ¸Å°´Â °ÍÀÌ 1Â÷°¨¿° ¶Ç´Â Ãʰ¨¿°ÀÌ´Ù. ÀÌ 1Â÷°¨¿°ÀÇ º´ÅÍÀÇ º´¿øÃ¼°¡ Ç÷°ü-¸²ÇÁ°ü-±â°ü-¼ÒÈ­°ü-¿ä°ü µîÀÇ ±æÀ» µû¶ó °°Àº ±â°üÀÇ ´Ù¸¥ ºÎÀ§³ª ´Ù¸¥ ±â°üÀ¸·Î ¿î¹ÝµÇ¾î °¨¿°À» ÀÏÀ¸Å²´Ù. µû¶ó¼­ 1Â÷°¨¿°¿¡ ÀÇÇÏ¿© ÃæºÐÇÑ ¸é¿ªÀÌ µÉ °æ¿ì¿¡´Â 2Â÷°¨¿°ÀÌ ÀϾÁö ¾Ê´Â´Ù. ¿¹¸¦ µé¾î, À¯Ç༺ °¨±â¿¡ °É·ÈÀ» ¶§ ¼¼±Õ¿¡ ÀÇÇÑ Æó·ÅÀÌ µÚµû¸£´Â °æ¿ì¸¦ À̸¥´Ù. Æó·Å±Õ, È­³ó¾Ë±Õ, ´ëÀå±Õ µûÀ§°¡ ÀÖ´Ù. 
¿µ¹® hypertension ÇÑ±Û °íÇ÷¾Ð
¼³¸í   
  µ¿¸ÆÀÇ Ç÷¾ÐÀÌ ³ôÀº °Í. ÀϹÝÀûÀ¸·Î ¸»Çϴ °íÇ÷¾ÐÀº ÀÌ µ¿¸Æ¼º °íÇ÷¾ÐÀ» ¸»ÇÑ´Ù. Ç÷¾ÐÀ̶õ Ç÷°ü¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»Çϴ °ÍÀ¸·Î ´ë°³ Æ¯ÀÌÇÑ ¼³¸íÀÌ ¾øÀ¸¸é µ¿¸ÆÀÇ ¾Ð·ÂÀ» ¸»ÇÑ´Ù. Ç÷¾Ð¿¡´Â ¼öÃà±âÇ÷¾Ð°ú À̿ϱâÇ÷¾ÐÀÌ ÀÖ´Ù. ¼öÃà±âÇ÷¾ÐÀ̶õ ½ÉÀåÀÌ ¼öÃàÇÒ ¶§ÀÇ µ¿¸Æ¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»Çϰí À̿ϱâ Ç÷¾ÐÀ̶õ ½ÉÀåÀÌ ÀÌ¿ÏÇÒ °æ¿ì¿¡ µ¿¸Æ¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»ÇÑ´Ù. ´ç¿¬È÷ ¼öÃà±â Ç÷¾ÐÀÌ À̿ϱâ Ç÷¾Ðº¸´Ù ³ô´Ù. Ç÷¾ÐÀ» ¸»ÇÒ ¶§¿¡ 120/80À̶ó°í Àû´Â °ÍÀÇ ¾ÕÀÇ °ÍÀº ¼öÃà±â Ç÷¾ÐÀ» ÀǹÌÇÏ°í µÚ¿¡ Àû´Â 80Àº À̿ϱâ Ç÷¾ÐÀ» ÀǹÌÇÑ´Ù.
  
  °íÇ÷¾ÐÀº ÁַΠÀ̿ϱâÀÇ Ç÷¾ÐÀ» ±âÁØÀ¸·Î Á¤ÇÑ´Ù. ¿©·¯ °¡Áö ±âÁØÀÌ ÀÖÀ¸³ª À̿ϱâ Ç÷¾ÐÀÌ 90mmHgÀÌ»óÀΠ°æ¿ì¸¦ ¸»ÇÑ´Ù. °íÇ÷¾Ð ÀÚü¿¡ ÀÇÇÑ Áõ»óÀº º°·Î ¾ø´Ù. ´Ù¸¸ °íÇ÷¾Ð¿¡ ÀÇÇÑ ÇÕº´Áõ°ú µ¿¸Æ°æÈ­ÀÇ ÃËÁø¿¡ ÀÇÇØ º´¹ßÇϴ Áúȯ¿¡ ÀÇÇÏ¿© Áõ»óÀÌ »ý±ä´Ù. °íÇ÷¾Ð¿¡ ÀÇÇÑ ÇÕº´ÁõÀº ´ë°³ Ç÷°ü¿¡ °É¸®´Â °úµµÇÑ ¾Ð·ÂÀ¸·Î ÀÎÇÑ Ç÷°üÀÇ ¼Õ»óÀÌ Áß¿äÇÑ ¿øÀÎÀÌ´Ù.
  
  °íÇ÷¾ÐÀº µ¿¸Æ°æÈ­ÀÇ ÁÖ¿ä À¯¹ßÀÎÀÚ ÁßÀÇ ÇϳªÀÌ´Ù. µ¿¸Æ°æÈ­´Â µ¿¸ÆÀÇ º®ÀÌ µÎÅÍ¿öÁö°í µ¿¸ÆÀ̠ź·ÂÀ» ÀÒ¾î¹ö¸®´Â ÁúȯÀÌ´Ù. ¾î¶² µ¿¸ÆÀÌ µ¿¸Æ°æÈ­¿¡ °É¸®¸é ÀÌ µ¿¸ÆÀº µÎÅÍ¿öÁø Ç÷°üº®¿¡ ÀÇÇØ¼­ ³»°æÀÌ ÀÛ¾ÆÁö°Ô µÈ´Ù. ÀÌ·¸°Ô µÇ¸é ±× µ¿¸ÆÀ¸·ÎºÎÅÍ Ç÷¾×À» °ø±Þ¹Þ´ø Àå±â´Â Ç÷¾×À» Àû°Ô °ø±Þ¹Þ°Ô µÇ°í ±× Á¤µµ°¡ ½ÉÇϰԠµÇ¸é ±× Àå±â´Â °á±¹ ¼Õ»óÀ» ÀÔ°Ô µÈ´Ù. µ¿¸Æ°æÈ­·Î ÀÎÇÑ Áúº´ÀÇ ´ëÇ¥ÀûÀΠ¿¹´Â ½ÉÀåÀÇ ±ÙÀ°¿¡ Ç÷¾×À» °ø±ÞÇϴ ½ÉÀ嵿¸Æ¿¡ µ¿¸Æ°æÈ­ÀÇ º¯È­°¡ ¿À´Â ½ÉÀ嵿¸Æº´ÀÌ´Ù.
  
  °íÇ÷¾ÐÀÇ Ä¡·á¿¡ ¾²À̴ ¾à¹°Àº ´ÙÀ½°ú °°Àº °ÍÀÌ ÀÖ´Ù.
  
  -ÀÌ´¢Á¦-ÄáÆÏ¿¡¼­ ¼öºÐ°ú ÀüÇØÁúÀÇ ¹èÃâÀ» ÃËÁø½Ã۴ ¾à¹°. Ã¼³»ÀÇ ¼öºÐÀÇ ¾çÀ» °¨¼Ò½ÃÄѼ­ Ç÷¾×ÀÇ È帣´Â ¾çÀ» Àû°ÔÇÏ°í ¶Ç Ç÷°üÁÖÀ§ Á¶Á÷ÀÇ ¼öºÐÀÇ °¨¼Ò·Î Ç÷°üÀ» È®Àå½Ã۴ ¿ªÇÒ(Ç÷°üÀÌ ÀÖ°í ±× Ç÷°üÀ» ½×°í Àִ Á¶Á÷¿¡ ¼öºÐÀÌ Â÷ ÀÖÀ¸¸é ±× Á¶Á÷ÀÌ Ç÷°üÀ» ´­·¯¼­ Ç÷°üÀÌ È®ÀåÇϴ °ÍÀ» ¹æÇØÇÑ´Ù)·Î Ç÷¾ÐÀ» °¨¼Ò½ÃŲ´Ù.
  
  -Ä®½·-Åë·ÎÂ÷´ÜÁ¦£­¸ðµç ±ÙÀ°ÀÇ ¼öÃà¿¡´Â Ä®½·ÀÌ ÇÊ¿äÇÏ´Ù. Áï Ç÷°üÀÇ ¼öÃà¿¡ °ü¿©Çϴ Ç÷°üµµ ¿ª½Ã ¼öÃàÀ» À§Çؼ­´Â Ä®½·ÀÌ ÇÊ¿äÇÏ´Ù. Ä®½·-Åë·ÎÂ÷´ÜÁ¦´Â ±ÙÀ°¼¼Æ÷ ¼ÓÀ¸·Î Ä®½·ÀÌ µé¾î°¡´Â °ÍÀ» ¹æÁöÇØ¼­ Ç÷°ü±ÙÀ°ÀÇ ¼öÃàÀ» ¹æÇØÇϰí À̷ΠÀÎÇØ¼­ Ç÷°üÀÇ È®ÀåÀ» À¯µµÇÑ´Ù.
  
  -¾ËÆÄÂ÷´ÜÁ¦, º£Å¸Â÷´ÜÁ¦-Ç÷°üÀº ÀÚÀ²½Å°æ°èÀÇ Áö¹è¸¦ ¹Þ´Â´Ù. ±×Áß¿¡¼­µµ Ç÷°üÀº ±³°¨½Å°æÀÇ ¿µÇâ¿¡ ÀÇÇØ¼­ ¼öÃà°ú ÀÌ¿ÏÀ» ÇÑ´Ù. ±³°¨½Å°æÀÇ ÀÛ¿ëÀº ±× ¼ö¿ëü¿¡ µû¶ó ´Þ¶óÁø´Ù. ±³°¨½Å°æÀÇ ¼ö¿ëüÀÇ Á¾·ù¿¡´Â ¾ËÆÄ¼ö¿ëü¿Í º£Å¸¼ö¿ëü°¡ ÀÖ´Ù. Ç÷°üÀ» Áö¹èÇϰí Àִ ±³°¨½Å°æ¿¡¼­ ¾ËÆÄ¼ö¿ëü´Â Ç÷°üÀÇ ¼öÃàÀ» ÀÏÀ¸Å°°í º£Å¸¼ö¿ëü´Â Ç÷°üÀÇ È®ÀåÀ» ÀÏÀ¸Å²´Ù. ±×·¯¹Ç·Î ¾ËÆÄ¼ö¿ëüÀÇ ÀÛ¿ëÀ» ¸·´Â °æ¿ì¿¡ Ç÷°üÀÇ È®ÀåÀ» À¯µµÇÒ ¼ö ÀÖ°í º£Å¸-¼ö¿ëüÀÇ ÀÛ¿ëÀ» Ç×Áø½Ãų °æ¿ì¿¡ ¿ª½Ã Ç÷°üÀÇ È®Á¤À» À¯µµÇÒ ¼ö ÀÖ´Ù.
¿µ¹® renal hypertension ÇÑ±Û ÄáÆÏ¼º°íÇ÷¾Ð
¼³¸í   
  ÄáÆÏ½ÇÁúÀÇ º´º¯À¸·Î ÀÎÇØ ¾ß±âµÈ °íÇ÷¾Ð. ÄáÆÏÀÇ ´ëÇ¥Àû ±â´ÉÀº ³ëÆó¹° ¹× ¼öºÐÀÇ ¹è¼³ÀÌ´Ù. ±×·±µ¥ ÀÌ·¯ÇÑ ÄáÆÏ±â´É¿¡ ÀÌ»óÀÌ »ý°åÀ» °æ¿ì Ã¼³»¿¡ °úÀ×¼öºÐÀÇ ÃàÀûÀÌ ¹ß»ýÇϰԠµÈ´Ù. À̿Ͱ°Àº °úÀ×¼öºÐÀÇ ÃàÀûÀº Ç÷°ü³» Á¤¼ö¾ÐÀ» »ó½Â½ÃÄÑ °íÇ÷¾ÐÀ» À¯¹ßÇϰԠµÈ´Ù. Ä¡·á´Â ¿øÀΠÄáÆÏº´ÀÇ ±³Á¤À̸ç ÀÌÀ¯¸¦ ¸ð¸£´Â ¿ø¹ß°íÇ÷¾Ð°ú ´Þ¸® ÄáÆÏ¼º°íÇ÷¾ÐÀÇ °æ¿ì¿¡´Â ¿øÀΠÄáÆÏº´ÀÌ ±³Á¤µÇ¸é °íÇ÷¾Ðµµ »ç¶óÁö°Ô µÈ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • secondary hypertension
    ÀÌÂ÷°íÇ÷¾Ð
  • endocrine
    1. ³»ºÐºñ- 2. È£¸£¸ó-
  • endocrine cataract
    ³»ºÐºñ¹é³»Àå
  • endocrine exophthalmos
    ³»ºÐºñ¾È±¸µ¹Ãâ(Áõ)
  • endocrine gland
    ³»ºÐºñ»ù, ³»ºÐºñ¼±
  • endocrine organ
    ³»ºÐºñ±â°ü
  • endocrine system
    ³»ºÐºñ°èÅë, ³»ºÐºñ°è
  • endocrine therapy
    ³»ºÐºñ¿ä¹ý
  • multiple endocrine adenomatosis
    ´Ù¹ß¼º³»ºÐºñ»ùÁ¾Áõ
  • multiple endocrine neoplasia
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç
  • multiple endocrine neoplasia 1
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç1Çü
  • multiple endocrine neoplasia 2
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç2Çü
  • multiple endocrine neoplasia 3
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç3Çü
  • accelerated hypertension
    °¡¼Ó°íÇ÷¾Ð
  • adrenal hypertension
    ºÎ½Å¼º°íÇ÷¾Ð
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • endocrine
    ³»ºÐºñ-
  • multiple endocrine neoplasia
    º¹ÇÕ³»ºÐºñ»ù½Å»ý¹°
  • hypertension
    °íÇ÷¾Ð
  • ocular hypertension
    °í¾È¾ÐÁõ
  • portal hypertension
    ¹®¸Æ°íÇ÷¾Ð
  • pregnancy-induced hypertension
    ÀӽŰíÇ÷¾Ð
  • pulmonary hypertension
    Æóµ¿¸Æ°íÇ÷¾Ð, ÇãÆÄ°íÇ÷¾Ð
  • renovascular hypertension
    ÄáÆÏÇ÷°ü°íÇ÷¾Ð, ½ÅÀåÇ÷°ü°íÇ÷¾Ð
  • sinusoidal hypertension
    ±¼Ç÷°ü°íÇ÷¾Ð
  • secondary sexual character
    ÀÌÂ÷¼ºÂ¡
  • secondary wound closure
    ÀÌÂ÷»óóºÀÇÕ
  • secondary dentition
    (¢¡permanent tooth) °£´Ï, ¿µ±¸Ä¡¾Æ
  • secondary hemostasis
    ÀÌÂ÷ÁöÇ÷
  • secondary infection
    ÀÌÂ÷°¨¿°
  • secondary nodule
    (¢¡germinal center) Á¾ÀÚÁß½É, ¹èÁß½É
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • secondary hypertension
    ÀÌÂ÷°íÇ÷¾Ð
  • multiple endocrine adenomatosis
    ´Ù¹ß³»ºÐºñ»ùÁ¾Áõ
  • endocrine cataract
    ³»ºÐºñ¹é³»Àå
  • endocrine
    ³»ºÐºñ
  • endocrine exophthalmos
    ³»ºÐºñ´«µ¹Ãâ(Áõ)
  • endocrine gland
    ³»ºÐºñ»ù
  • endocrine organ
    ³»ºÐºñ±â°ü
  • endocrine system
    ³»ºÐºñ°èÅë
  • endocrine therapy
    ³»ºÐºñ¿ä¹ý
  • multiple endocrine neoplasia
    º¹ÇÕ³»ºÐºñ»ù½Å»ý¹°
  • accelerated hypertension
    °¡¼Ó°íÇ÷¾Ð
  • adrenal hypertension
    ºÎ½Å°íÇ÷¾Ð
  • borderline hypertension
    °æ°è°íÇ÷¾Ð
  • diastolic hypertension
    È®Àå±â°íÇ÷¾Ð
  • essential hypertension
    º»Å°íÇ÷¾Ð
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gastrointestinal endocrine cell
    À§Ã¢ÀÚ³»ºÐºñ¼¼Æ÷
  • haploid secondary gametocyte
    Ȭ¹è¼öüÀÌÂ÷»ý½Ä¼¼Æ÷
  • immune response, secondary
    ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • immunodeficiency syndrome, secondary
    ÀÌÂ÷¼º ¸é¿ª°áÇÌ ÁõÈıº, ¼Ó¹ß¼º ¸é¿ª°áÇÌ ÁõÈıº
  • infection, secondary
    ÀÌÂ÷°¨¿°
  • process, secondary (psychic)
    ÀÌÂ÷°úÁ¤.
  • DSM-I=Diagnostic and Statistical Manual of Mental Disorders-I
    Á¤½ÅÀå¾Ö(º´)Áø´ÜÅë°èÆí¶÷ Á¦ 1ÆÇ
  • SADS, Schedule for Affective Disorders and Schizophrenia
    Á¤µ¿Àå¾Ö¿Í Á¤½ÅºÐ¿­º´ÀÇ Áø´ÜÀ» À§ÇÑ ¸ñ·Ï
  • adrenal disorders
    ºÎ½ÅÀå¾Ö, ºÎ½ÅÁúȯ.
  • genetic disorders
    À¯Àü¼º Àå¾Ö(Áúȯ)(ë¶îîàõ î¡äô)
  • hemostatic disorders
    Ç÷¾×ÀÀ°íÁúȯ
  • hypersensitivity disorders
    °ú¹Î¼º Áúȯ(ΦÚÂàõ òðü´)
  • immune disorders
    ¸é¿ªÀå¾Ö(Øóæ¹î¡äô)
  • platelet function disorders
    Ç÷¼ÒÆÇ±â´ÉÀÌ»óÁúȯ
  • postpartum disorders
    »êÈÄ Àå¾Ö(º´)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • secondary hypertension
    ÀÌÂ÷¼º °íÇ÷¾Ð (¡­ÍÔúìäâ).
  • secondary hypertension
    ÀÌÂ÷¼º °íÇ÷¾Ð (¡­ÍÔúìäâ)
  • secondary yolk sac [secondary vitelline sac]
    ÀÌÂ÷³­È²ÁÖ¸Ó´Ï
  • cortical endocrine cell
    °ÑÁú³»ºÐºñ¼¼Æ÷
  • discrete multiple endocrine adenomatosis syndrome
    ºÐ¸®¼º ´Ù¹ß ³»ºÐºñ¼±Á¾ ÁõÈıº(ÝÂìÆàõÒýÛ¡Ò®ÝÂù²àÍðþñøý¦ÏØ).
  • endocrine
    ³»ºÐºñ(Ò®ÝÂÝô)
  • endocrine cataract
    ³»ºÐºñ¼º¹é³»Àå
  • endocrine cell
    ³»ºÐºñ ¼¼Æ÷(Ò®ÝÂÝô á¬øà)
  • endocrine cell
    ³»ºÐºñ¼¼Æ÷
  • endocrine cell cluster
    ³»ºÐºñ¼¼Æ÷¹«¸®
  • endocrine cell of pineal gland
    ¼Û°úü³»ºÐºñ¼¼Æ÷
  • endocrine cell tumor
    ³»ºÐºñ ¼¼Æ÷ Á¾¾ç(¡­ðþåË)
  • endocrine exophthalmos
    ³»ºÐºñ¼º¾È±¸µ¹Ãâ(Áõ).
  • endocrine fracture
    ³»ºÐºñ¼º °ñÀý(Ò®ÝÂÝôàõÍéï½).
  • endocrine gland
    ³»ºÐºñ¼±(Ò®ÝÂù²àÊ)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Secondary yolk sac [Secondary vitelline sac]
    ÀÌÂ÷³­È²ÁÖ¸Ó´Ï
    [¿¾ ¿ë¾î] ÀÌÂ÷³­È²³¶
  • Cortical endocrine cell
    °ÑÁú³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ÇÇÁú³»ºÐºñ¼¼Æ÷
  • ENDOCRINE GLAND
    ³»ºÐºñ»ù
    [¿¾ ¿ë¾î] ³»ºÐºñ¼±
  • ENDOCRINE GLANDS
    ³»ºÐºñ»ù
    [¿¾ ¿ë¾î] ³»ºÐºñ¼±
  • Medullary endocrine cell
    ¼ÓÁú³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ¼öÁú³»ºÐºñ¼¼Æ÷
  • Endocrine cell of pineal gland
    ¼Û°úü³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ¼Û°úü³»ºÐºñ¼¼Æ÷
  • Gastrointestinal endocrine cell
    À§Ã¢ÀÚ³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] À§Ã¢ÀÚ³»ºÐºñ¼¼Æ÷
  • Pancreatic endocrine cell
    ÀÌÀÚ³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ÃéÀå³»ºÐºñ¼¼Æ÷
  • Endocrine cell
    ³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ³»ºÐºñ¼¼Æ÷
  • Secondary segmental bronchus
    ±¸¿ª±â°üÁö°¡Áö
    [¿¾ ¿ë¾î] ÀÌÂ÷±¸±â°üÁö
  • Secondary tympanic membrane
    µÑ°°í¸·
    [¿¾ ¿ë¾î] Á¦ÀÌ°í¸·
  • Secondary spiral lamina
    µÑ°³ª¼±ÆÇ
    [¿¾ ¿ë¾î] Á¦2³ª¼±ÆÇ
  • Secondary fissure
    µÑ°ƴ»õ
    [¿¾ ¿ë¾î] Á¦2¿­
  • Secondary polar body
    ÀÌÂ÷±ØÃ¼
    [¿¾ ¿ë¾î] ÀÌÂ÷±ØÃ¼
  • Secondary oocyte
    ÀÌÂ÷³­¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] ÀÌÂ÷³­¸ð¼¼Æ÷
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • secondary amebic meningoencephalitis
    ÀÌÂ÷¾Æ¸Þ¹Ù¼ö¸·³ú¿°
  • secondary echinococcosis
    ÀÌÂ÷Æ÷ÃæÁõ
  • secondary infection
    ÀÌÂ÷°¨¿°
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • renal hypertension
    ½Å°íÇ÷¾Ð(ãìÍÔúìäâ)
  • endocrine gland
    ³»ºÐºñ¼±(Ò®ÝÂÝôàÍ)
  • endocrine hormones
    ³»ºÐºñ¼±(Ò®ÝÂÝôàÍ) È£¸£¸ó
  • endocrine system
    ³»ºÐºñ¼±(Ò®ÝÂù²àÊ) ½Ã½ºÅÛ
  • secondary acidosis
    ÀÌÂ÷ »êÁõ(ì£ó­ß«ñø)
  • secondary active transport
    ÀÌÂ÷ ´Éµ¿¼ö¼Û(ì£ó­ÒöÔÑâÃáê)
  • secondary alkalosis
    ÀÌÂ÷(ì£ó­) ¾ËÄ®¸®Áõ(ñø)
  • secondary bile acid
    ÀÌÂ÷ ´ãÁó»ê(ì£ó­ÓÅñðß«)
  • secondary bond
    ÀÌÂ÷ °áÇÕ(ì£ó­Ì¿ùê)
  • secondary charge effect
    ÀÌÂ÷ ÇÏÀüÈ¿°ú(ì£ó­ùÃï³üùÍý)
  • secondary culture
    ÀÌÂ÷ ¹è¾ç(ì£ó­ÛÆå×)
  • secondary deficiency
    ÀÌÂ÷ °áÇÌ(ì£ó­ÌÀù¹)
  • secondary derived protein
    ÀÌÂ÷ À¯µµ´Ü¹éÁú(ì£ó­ë¯ÓôÓ±ÛÜòõ)
  • secondary electron
    ÀÌÂ÷ ÀüÀÚ(ì£ó­ï³í­)
  • secondary fluor
    ÀÌÂ÷ Çü±¤Á¦(ì£ó­û«ÎÃð¥)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • endocrine
    ³»ºÐºñÀÇ
  • endocrine disease
    ³»ºÐºñÁúȯ
  • essential hypertension
    º»Å¼º°íÇ÷¾Ð
  • hypertension
    °íÇ÷¾ÐÁõ, ±äÀåÇ×ÁøÁõ
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾ÐÁõ
  • portal hypertension
    ¹®¸Æ¾ÐÇ×ÁøÁõ, ¹®¸Æ°íÇ÷¾Ð
  • primary hypertension
    ¿ø¹ß(¼º)°íÇ÷¾ÐÁõ
  • renal hypertension
    ½Å¼º°íÇ÷¾Ð
  • renovascular hypertension
    ½ÅÇ÷°ü¼º°íÇ÷¾Ð
  • splenoportal hypertension
    ºñ¹®¸Æ¼º°íÇ÷¾ÐÁõ
  • secondary
    ÀÌÂ÷(¼º)ÀÇ, ¼Ó¹ß(¼º)ÀÇ
  • secondary anemia
    ¼Ó¹ß¼ººóÇ÷
  • secondary infection
    ÀÌÂ÷°¨¿°, ¼Ó¹ß°¨¿°
  • secondary lesion
    ÀÌÂ÷¼ºº´º¯, ÀÌÂ÷¹ßÁø, ¼Ó¹ßÁø
  • secondary ossification center
    ÀÌÂ÷°ñÈ­Áß½É
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SA salicylic acid; saline [solution]; salt added; sarcoidosis; sarcoma; scalenus anticus; secondary ame...
JVP [POMD P 49 - 52]
  1) Jugular Vein Pressure
  2) Jugular Venous Pulse
...
MEN Multiple Endocrine Neoplasia
  ; AD Trait
  1. MEN Type I(= Wermer Syndro...
PRAGMATIC pregnancy, rheumatoid arthritis, acromegaly, glucose metabolism disorders, mechanical injury, amyloi...
HSRD hypertension secondary to renal disease
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
STOP Hypertension Swedish Trial in Old Patients with Hypertension
LSIMS Liquid secondary ion mass spectrometry
S Secondary
SIMS Secondary Ion Mass Spectrometry
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • I15.2
    Hypertension secondary to endocrine disorders
    ³»ºÐºñ Àå¾Ö¿¡ ¼Ó¹ßµÈ °íÇ÷¾Ð
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • American Academy of Craniomandibualr Disorders
    ¹Ì±¹ µÎ°³ÇϾÇÀå¾ÖÇÐȸ
  • discrete multiple endocrine adenomatosis syndrome
    ºÐ¸®¼º ´Ù¹ß ³»ºÐºñ ¼±Á¾ ÁõÈıº
  • endocrine diabetes
    ³»ºÐºñ¼º ´ç´¢º´
  • endocrine disorder
    ³»ºÐºñ Àå¾Ö
  • endocrine exophthalmos
    ³»ºÐºñ¼º ¾È±¸ µ¹Ãâ, ³»ºÐºñ¼º ¾È±¸ µ¹ÃâÁõ
  • endocrine gland
    ³»ºÐºñ »ù, ³»ºÐºñ ¼±
    1. Ç¥¸é°ú ¿¬°áµÊÀÌ ¾øÀÌ Ç÷°ü ¼ÓÀ¸·Î ºÐºñÇÏ´Â »ù. 2. È£¸£¸óÀ» ºÐºñÇÏ´Â ¼±. ¿ÜºÐºñ¼±°ú °°Àº µµ°üÀÌ ¾ø°í È£¸£¸óÀº Á÷Á¢ ü¾× ¼ÓÀ¸·Î ¹èÃâµÈ´Ù.
  • endocrine organ
    ³»ºÐºñ ±â°ü
    ³»ºÐºñ ±â´ÉÀ» ´ã´çÇÏ´Â ½Åü ±â°üÀ¸·Î ³úÇϼöü, ½Ã»ó ÇϺÎ, °©»ó¼±, ÃéÀå, ºÎ½Å, ºÎ°©»ó¼±°ú »ý½Ä ±â°üÀÌ ÀÖ´Ù.
  • endocrine system
    ³»ºÐºñ°è
    ÀÎüÀÇ Á¶Àý ±â´ÉÀ¸·Î ¼¼Æ÷°£ÀÇ ´ëÈ­¸¦ È­ÇÐ ¹°ÁúÀΠȣ¸£¸óÀ» ÅëÇØ¼­ È­ÇÐÀûÀÎ ½ÅÈ£¸¦ ÀÌ¿ëÇÏ¿© Ç¥Àû ¼¼Æ÷µé¿¡ ÀÛ¿ëÇÑ´Ù. ÈçÇÑ ³»ºÐºñ°è ÀÌ»óÀº ºñÁ¤»óÀûÀÎ ¼ºÀå, ¿¡³ÊÁö ¼öÁØ º¯È­ ¿Âµµ º¯È­¿¡ÀÇ ºÎÀûÀÀ ¹× ¼³¸íµÇÁö ¾Ê´Â üÁß º¯È­·Î ³ªÅ¸³­´Ù. ´Ù´¢, °úµµÇÑ °¥Áõ, üÁß °¨¼Ò¸¦ µ¿¹ÝÇÑ ½Ä¿å °ú´Ù´Â ´ç´¢º´ÀÇ Æ¯Â¡ÀÌ´Ù. ½Ã·Â º¯È­, ½ÅÀå ±â´ÉÀå¾Ö, »çÁöÀÇ Ç÷¾× ¼øÈ¯ °¨¼Ò´Â Àå±â°£ÀÇ ´ç´¢·Î ÀÎÇÑ ÁøÇàµÈ Ç÷°ü °æÈ­ÀÇ Áõ»óÀÌ´Ù.
  • multiple endocrine neoplasia
    ´Ù¹ß¼º ³»ºÐºñ Á¾¾ç
  • accelerated hypertension
    °¡¼Ó¼º °íÇ÷¾Ð
  • essential hypertension
    º»Å¼º °íÇ÷¾Ð
    1. Ưº°ÇÑ ¿øÀÎÀÌ ¾Ë·ÁÁöÁö ¾ÊÀº °íÇ÷¾ÐÀ» ÀǹÌÇϸç ÀÌ´Â Àüü °íÇ÷¾Ð ȯÀÚÀÇ 85-90£¥¸¦ Â÷ÁöÇÑ´Ù. 2. À¯Àü, Á¤½ÅÀû ½ºÆ®·¹½º, ¿°ºÐÀÇ Áõ°¡ µî Ç÷¾Ð »ó½ÂÀÌ º¹ÇÕÀûÀÎ ¿øÀÎ ÇüÅ·Π³ªÅ¸³­´Ù.
  • hypertension paroxystique
    ºÒ ¹ßÀÛ¼º °íÇ÷¾Ð
  • juvenile hypertension
    ¿¬¼Ò¼º °íÇ÷¾ÐÁõ, ¿¬¼Ò¼º °íÇ÷¾Ð
  • labile hypertension
    ºÒ¾ÈÁ¤¼º °íÇ÷¾Ð
  • nephrogenous hypertension
    ½Å¼º °íÇ÷¾Ð
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
endocrine disorders Disorders which involve the over-production or under-production of hormone substances from an endocrine gland. Some examples include diabetes, hypothyroidism, hyperthyroidism, hyperparathyroidism, Cushing's disease, Cushing's syndrome and acromegaly.
(27 Sep 1997)
secondary hypertension Arterial hypertension produced by a known cause, e.g., hyperthyroidism, kidney disease, etc., in contrast to primary hypertension that is of unknown cause.
(05 Mar 2000)
bone diseases, endocrine Diseases of the bones related to hyperfunction or hypofunction of the endocrine glands.
(12 Dec 1998)
multiple endocrine adenomatosis The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance.
Synonym: multiple endocrine adenomatosis.
(05 Mar 2000)
multiple endocrine deficiency syndrome <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis.
Synonym: multiple glandular deficiency syndrome.
(05 Mar 2000)
multiple endocrine neoplasia (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour.
(type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
Origin: Gr. Plassein = to form
(27 Sep 1997)
multiple endocrine neoplasia 1 <radiology> Multiple endrocrine neoplasia syndrome three P's.
Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH
pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression
Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%).
Synonym: Wermer syndrome
(12 Dec 1998)
multiple endocrine neoplasia 2 <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia
Synonym: Sipple syndrome
(12 Dec 1998)
multiple endocrine neoplasia 3 <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B
Synonym: Schimke, marfanoid syndrome
(12 Dec 1998)
multiple endocrine neoplasia type 1 A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients.
(12 Dec 1998)
multiple endocrine neoplasia type 2 <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
(27 Sep 1997)
multiple endocrine neoplasia type 2a A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands.
(12 Dec 1998)
multiple endocrine neoplasia type 2b A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas.
(12 Dec 1998)
neoplastic endocrine-like syndromes Endocrine syndromes due to hormone production by neoplasms of non-endocrine tissue, or by other than the usual endocrine tissues. They are often the first indication of a previously undetected neoplasm.
(12 Dec 1998)
diagnostic techniques, endocrine Methods and procedures for the diagnosis of diseases or dysfunction of the endocrine glands or demonstration of their physiological processes.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hypertension
    °íÇ÷¾Ð; °úµµ ±äÀå
  • endocrine
    ³»ºÐºñÀÇ;³»ºÐºñ¹°;È£¸£¸ó;³»ºÐºñ¼±
  • endocrine gland
    (»ý¸®)³»ºÐºñ¼±
  • hypertension
    °íÇ÷¾Ð
  • secondary
    Á¦ 2ÀÇ
  • post secondary education
    Áßµî °úÁ¤ ÈÄÀÇ ±³À°
  • secondary
    µÑ°ÀÇ;ÁßµîÀÇ;º¸Á¶ÀÚ;´ë¸®ÀÚ
  • secondary accent
    Á¦ 2¾×¼¾Æ®
  • secondary ballot
    °á¼± ÅõÇ¥
  • secondary base
    2·ç
  • secondary education
    Áßµî ±³À°
  • secondary industry
    Á¦ 2Â÷ »ê¾÷
  • secondary school
    Áßµî Çб³
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á